Country: Canada
Language: English
Source: Health Canada
LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE
MINT PHARMACEUTICALS INC
C09DA01
LOSARTAN AND DIURETICS
50MG; 12.5MG
TABLET
LOSARTAN POTASSIUM 50MG; HYDROCHLOROTHIAZIDE 12.5MG
ORAL
30/100/1000
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0233168001; AHFS:
APPROVED
2012-07-27
_MINT-LOSARTAN/HCTZ and MINT-LOSARTAN/HCTZ_ _ _ _DS _ _(losartan potassium and hydrochlorothiazide) _ _Page 1 of 44_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MINT-LOSARTAN/HCTZ losartan potassium and hydrochlorothiazide tablets Tablets, 50 mg / 12.5 mg and 100 mg / 12.5 mg, Oral Pr MINT-LOSARTAN/HCTZ DS losartan potassium and hydrochlorothiazide tablets Tablets, 100 mg / 25 mg, Oral House Standard Angiotensin II Receptor Antagonist and Diuretic MINT PHARMACEUTICALS INC. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Date of Initial Authorization: JUL 27, 2012 Date of Revision: FEB 14, 2023 Submission Control Number: 267752 _MINT-LOSARTAN/HCTZ and MINT-LOSARTAN/HCTZ_ _ _ _DS _ _(losartan potassium and hydrochlorothiazide) _ _Page 2 of 44_ _ _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Respiratory 02/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .............................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................... Read the complete document